

Supplemental Figure 1. Receptor expression and NK cytotoxicity analyzed ex-vivo in NK cells of FK-506-treated patients after transplantation. (A) Expression of CD2, NKG2D, 2B4, and CD48 on NK cells was shown in the healthy age-matched controls (n=6) and patients on FK506 (n=7). Y axis represents MFI (mean fluorescence intensity) of individual receptors. (B) CD107a degranulation assay against K562 targets was performed using ex-vivo PBMCs from the healthy control (n=6) and FK506-treated group (n=7). The percentage of CD107a positive population among CD3⁻CD56⁺ cells was shown. Independent sample t test was performed by SPSS.

Supplemental Figure 2. CD16⁻CD56⁺ and CD16⁺CD56⁺ NK cell populations were not significantly changed by FK506. The percentages of CD16⁻CD56⁺ and CD16⁺CD56⁺ NK cells were assessed by flow cytometry after 7 days in IL-2 culture with/without 10 ng/ml FK506 (n=19). (A) NK cell subpopulations were plotted as bar graphs to show their averages with standard deviation. (B) NK cell subpopulations from individual donors were plotted.